Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actomyosin ATPase is the enzyme activity that arises from the interaction of myosin (most often myosin II in muscle) with actin filaments, resulting in ATP hydrolysis coupled to force generation and movement[1][3][4]. In the muscle contractile cycle, binding of ATP to the myosin head causes dissociation from actin, hydrolysis of ATP induces a conformational change in myosin (cocking), and subsequent binding to actin and release of phosphate and ADP drives the power stroke and filament sliding[1][3]. This cycle underlies muscle contraction and many other force-generating processes in cells. Pathological alterations to actomyosin ATPase activity contribute to various muscle and cardiac diseases, and this target is pharmacologically modulated by several drugs for conditions like heart failure and hypertrophic cardiomyopathy[1][3][4].
Inhibition of ATP hydrolysis (decreases contractility) Activation or sensitization of ATPase (increases contractility)
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actomyosin ATPase.